Imunoterapija raka debeloga crijeva
| Autor: | Antonio Juretić |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry Colorectal cancer medicine.medical_treatment Microsatellite instability General Medicine Immunotherapy colorectal cancer biomarkers immunotherapy immunooncology microsatellite instability mismatch repair deficiency personalized medicine medicine.disease kolorektalni rak biomarkeri imunoterapija imunoonkologija mikrosatelitska nestabilnost manjak popravka krivo sparenih baza DNA personalizirana medicina Internal medicine Immunooncology MISMATCH REPAIR DEFICIENCY Medicine Personalized medicine business |
| Zdroj: | Rad Hrvatske akademije znanosti i umjetnosti. Medicinske znanosti Issue 533=45 |
| ISSN: | 1848-641X 1330-5301 |
| Popis: | Recent successful results of a relatively new immunotherapeutic anti-cancer strategy based on the blockade of immune inhibitory pathways by monoclonal antibodies against checkpoint molecules can be considered as a medical breakthrough in clinical cancer immunotherapy. This type of immunotherapy became a standard part of systemic therapy protocols in the treatment of some metastatic solid tumors such as melanoma, non-small cell lung cancer, genitourinary cancers, Merkel-cell carcinoma, squamous-cell carcinoma of the head and neck, and solid tumors with DNA high microsatellite instability or DNA mismatch-repair deficiency. Recent progress in colorectal cancer genome analysis, and also supported by clinical observations, indicates that patients with DNA mismatch repair deficiency or microsatellite instability-high metastatic colorectal cancers are a distinct biomarker-defined population that might benefit from immunotherapy treatment with monoclonal antibodies against checkpoint molecules. This treatment has therefore become a new treatment option for this colorectal cancer subgroup of patients. However, besides tumor microsatellite instability or mismatch-repair deficiency status, other predictive biomarkers are also needed since not all these tumors respond to anti-check point immunotherapy treatment. This paper aims to present a basic overview of immunotherapy in mismatch repair deficient colorectal cancer patients. Nedavni uspješni rezultati razmjerno novog imunoterapijskog pristupa baziranog na blokadi imunoloških inhibitornih molekularnih puteva s monoklonskim antitijelima protiv molekula kontrolnih točaka mogu se smatrati medicinskim iskorakom u kliničkoj onkologiji. Taj tip imunoterapije postao je standardni dio protokola sistemne terapije nekih metastatskih tumora poput melanoma, raka nemalih stanica pluća, genitourinarnog karcinoma, karcinoma Merkelovih stanica, raka pločastih stanica glave i vrata i solidnih tumora s visokom mikrosatelitskom nestabilnošću ili manjkom popravka krivo sparenih baza DNA. Noviji rezultati molekularnih analiza genoma raka debelog crijeva, također poduprti kliničkim opažanjima, upućuju na to da su bolesnici s karcinomima u kojih postoji izražena mikrosatelitska nestabilnost ili nemogućnost popravka krivo sparenih baza DNA zasebna biomarkerom definirana populacija koja može imati koristi od liječenja monoklonskim antitijelima protiv imunoloških molekula kontrolnih točaka. Na temelju tih rezultata taj je imunoterapijski pristup postao nova terapijska opcija za tu podskupinu bolesnika s kolorektalnim rakom. Pa ipak, uz mikrosatelitsku nestabilnosti ili nemogućnost popravka krivo sparenih baza DNA potrebni su i drugi biomarkeri jer je taj imunoterapijski pristup učinkovit samo u dijelu tih bolesnika. Cilj je ovoga rada dati osnovni prikaz imunoterapije u tih bolesnika. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|